SNAP-25 reduction in the hippocampus of patients with schizophrenia

Peter M. Thompson, Shirley Egbufoama, Marquis P. Vawter

Research output: Contribution to journalArticlepeer-review

101 Scopus citations


In this study, the authors sought to replicate the findings of reduced synaptosomal associated protein 25 kDa (SNAP-25) immunoreactivity in the hippocampus of patients with schizophrenia. The authors also measured N-methyl-D-aspartate (NMDA) receptor 1 (NR1) receptor subunit to determine if glutamatergic synapses were involved with the loss of SNAP-25. We found 49% less SNAP-25 immunointensity in the schizophrenic group (n=7) compared to the control (n=8) or bipolar groups (n=4) (P=.004). There was no change in NMDA NR1 levels in the three groups. The authors confirm the previous report of less SNAP-25 immunoreactivity in the hippocampus using a different cohort of patients with schizophrenia. It also appears that NMDA NR1 was unchanged, indicating that the overall level of NMDA glutamatergic synapses in hippocampus is normal. These data add to evidence suggesting that in schizophrenia the molecular pathology of the hippocampus involves presynaptic components.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number3
StatePublished - May 2003


  • Bipolar illness
  • Exocytosis
  • NMDA
  • NR1
  • SNAP-25
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry


Dive into the research topics of 'SNAP-25 reduction in the hippocampus of patients with schizophrenia'. Together they form a unique fingerprint.

Cite this